Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Download PDF
Thromb Haemost 1999; 82(02): 500-504
DOI: 10.1055/s-0037-1615871
DOI: 10.1055/s-0037-1615871
Research Article
The Role of Genetics in Inhibitor Formation
Further Information
Publication History
Publication Date:
09 December 2017 (online)
Introduction
Treatment of hemorrhages in patients with inherited severe hemophilia A is dependent on transfusion replacement therapy with either plasma-derived or recombinant factor VIII concentrates.1 Hemorrhages become very difficult to treat after inhibitors develop, resulting in significant decreases in qualityof- life and life expectancy.2-6 Strategies to treat hemorrhages in the face of an inhibitor include the use of “bypass” therapy with activated and nonactivated prothrombin complex concentrates, high-dose factor VIII, porcine factor VIII, and recombinant factor VIIa. None of these is as effective as treatment of the noninhibitor patient with factor VIII.2,6 Therefore, several strategies to induce tolerance to factor VIII administration have been attempted, including administration of daily high-dose intravenous infusions of factor VIII concentrate alone, or in combination with, immune-modulating therapy.2,6 These strategies are extraordinarily difficult and expensive and are frequently unsuccessful, particularly when the inhibitor is well established. Thus, the ability to predict which patients are at risk for inhibitor development and to identify factors that predispose to inhibitor development would allow investigation of therapies targeted to prevent the establishment of the inhibitor response or to provide the ability to initiate early and, thus, more effective, immune tolerance induction for those at risk.
-
References
- 1 Gill JC. Therapy of factor VIII deficiency. Semin Thromb Haemost 1993; 19: 1-12.
- 2 Kasper C. Treatment of factor VIII inhibitors. Prog Hemost Thromb 1989; 9: 57-86.
- 3 McMillan CW, Shapiro SS, Whitehurst D. The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. Blood 1988; 71: 344-348.
- 4 Ehrenforth S, Kreuz W, Scharrer I, Linde R, Funk M, Gungor T, Krackhardt B, Kornhuber B. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-598.
- 5 Sultan Y. for the French Hemophilia Study Group. Prevalence of inhibitors in a population of 3435 hemophilia patients in France. Thromb Haemost 1992; 67: 600-602.
- 6 Lusher J. Management of patients with factor VIII inhibitors. Transfus Med Rev 1987; 1: 123-130.
- 7 Schwarzinger I, Pablinger I, Korninger C, Haschke G, Kundi M, Niessner H, Lechner K. Incidence of inhibitors in patients with severe and moderate hemophilia A treated with factor VIII concentrates. Am J Hematol 1987; 24: 241-245.
- 8 Peerlinck K, Rosendaal FR, Vermylen J. Incidence of inhibitor development in a group of young hemophilia A patients treated exclusively with lyophilized cryoprecipitate. Blood 1993; 81: 3332-3335.
- 9 Addiego J, Kasper C, Abildgaard C, Hilgartner M, Lusher J, Glader B, Aledort LM. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII. Lancet 1993; 342: 462-464.
- 10 de Biasi R, Rocino A, Papa L, Salerno E, Mastrullo L, De Blasi D. Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates. Thromb Haemost 1994; 71: 544-547.
- 11 Guerois C, Laurian Y, Rothschild C, Parquet-Gernez A, Duclos A, Negrier C, Vicariot M, Fimbel B, Fressinaud E, Fiks-Sigaud M, Derlon A, Berthier A, Gaillard S, Bertrand M. Incidence of factor VIII inhibitor development in severe hemophilia A patients treated only with one brand of highly purified plasma-derived concentrate. Thromb Haemost 1995; 73: 215-218.
- 12 Bray GL, Gomperts ED, Courter S, Gruppo R, Gordon EM, Manco-Johnson M, Shapiro A, Scheibel E, White G, Lee M. for the Recombinant Study Group. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. Blood 1994; 83: 2428-2435.
- 13 Lusher J, Arkin S, Abildgaard C, Schwartz RS. for the Kogenate Previously Untreated Patient Study Group. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. N Engl J Med 1993; 328: 453-459.
- 14 McMillan CW, Shapiro SS, Whitehurst D, Hoyer LW, Rao AV, Lazerson J. The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors. Blood 1988; 71: 344-348.
- 15 Hoyer LW. The incidence of factor VIII inhibitors in patients with severe hemophilia A. In : Aledort LM. ed. Inhibitors to Coagulation Factors. Plenum Press; New York: 1995: 35.
- 16 Peerlinck K, Arnout J, Di Giambattista M, Gilles JG, Laub R, Jacquemin M, Saint-Remy JM, Vermylen J. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate. Thromb Haemost 1997; 77: 80-86.
- 17 Rosendaal FR, Nieuwenhuis HK, van den Berg HM, Heijboer H, Mauser-Bunschoten EP, van der Meer J, Smit C, Strengers PFW. for the Dutch Haemophilia Study Group. A sudden increase in factor VIII inhibitor development in multitransfused haemophilia A patients in The Netherlands. Blood 1993; 81: 2180-2186.
- 18 Bray GL, Kroner BL, Arkin S, Aledort LM, Hilgartner M, Eyster ME, Ragni MV, Goedert JJ. Loss of high-responder inhibitors in patients with severe hemophilia A and human immunodeficiency virus Type 1 infection: a report from the Multi-Center Hemophilia Cohort Study. Am J Hematol 1993; 42: 375-379.
- 19 European Study Group of Factor VIII Antibody. Development of factor VIII antibody in haemophilic monozygotic twins. Scan J Haematol 1979; 23: 64-68.
- 20 Shapiro SS. Genetic predisposition to inhibitor formation. Prog Clin Biol Res 1984; 150: 45-55.
- 21 Frommel D, Allain JP. Genetic predisposition to develop factor VIII antibody in classic hemophilia. Clin Immuno Immunopathol 1977; 8: 34-38.
- 22 Giles AR, Tinlin S, Hoogendoorn H, Greenwood P, Greenwood R. Development of factor VIII:C antibodies in dogs with hemophilia A (Factor VIII:C deficiency). Blood 1984; 63: 451-456.
- 23 Tinlin S, Webster S, Giles AR. The development of homologous (canine/anti-canine) antibodies in dogs with haemophilia A (factor VIII deficiency): a ten-year longitudinal study. Thromb Haemost 1993; 69: 21-24.
- 24 Schwaab R, Brackmann HH, Meyer C, Seehafer J, Kirchgesser M, Haack A, Olek K, Tuddenham EGD, Oldenburg J. Haemophilia A. Mutation type determines risk of inhibitor formation. Thromb Haemost 1995; 74: 1402-1406.
- 25 Tuddenham EGD, McVey JH. The genetic basis of inhibitor development in haemophilia A. Haemophilia 1998; 4: 543-545.
- 26 Antonarakis SE, Rossiter JP, Young M, Horst J, de Moerloose P, Sommer SS, Ketterling RP, Kazazian JJ, Negrier C, Vinciguerra C, Gitschier J, Goossens M, Girodon E, Ghanem M, Plassa F, Lavergne JM, Vidaud M, Costa JM, Laurian Y, Lin S, Lin S, Shen M, Lillicrap D, Taylor SAM, Windsor S, Valleix SB, Nafa K, Sultan Y, Delpech M, Vnencak-Jones CL, Phillips III JA, Ljung RCR, Koumbarelis E, Gialeraki A, Mandalaki T, Jenkins PV, Collins PW, Pasi J, Goodeve AC, Peake IR, Preston FE, Schwartz M, Scheibel E, Ingerslev J, Cooper DN, Millar DS, Kakkar VV, Giannelli F, Naylor JA, Tizzano EF, Baiget M, Domenech M, Altisent C, Tusell J, Beneyto M, Lorenzo JI, Gaucher C, Mazurier C, Peerlinck K, Matthijs G, Cassiman JJ, Vermylen J, Mori PG, Acquila M, Caprino D, Inaba J. Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. Blood 1995; 86: 2206-2212.
- 27 Gill JC, Lessinger C, Kasper C, Sexhauer C, Inwood M, Cohen A. for the HRS Inhibitor Registry Investigators. Hemophilia inhibitors in the 80s and 90s: a first look at the Hemophilia Research Society Inhibitor Registry. Blood 1996; 88: 330a.
- 28 Lavergne JM, Meyer D, Reisner H. Characterization of human anti-factor VIII antibodies purified by immune complex formation. Blood 1976; 48: 931-939.
- 29 Shapiro SS. Characterization of factor VIII antibodies. Ann N Y Acad Sci 1975; 240: 350-361.
- 30 Allain JP, Frommel D. Antibodies to factor VIII: specificity and kinetics of iso- and hetero-antibodies in hemophilia A. Blood 1974; 44: 313-322.
- 31 Fulcher CA, De Graaf Mahoney S, Zimmerman TS. FVIII inhibitor IgG subclasss and FVIII polypeptide specificity determined by immunoblotting. Blood 1987; 69: 1475-1480.
- 32 Gilles JG, Armout J, Vermylen J, Saint-Remy JM. Anti-factor VIII antibodies of hemophilic patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction. Blood 1993; 82: 2452.
- 33 Schultz CL, Coffman RL. Control of isotype switching by T cells and cytokines. Curr Opin Immunol 1991; 3: 350-354.
- 34 Punnonen J, Aversa G, Cocks BG, McKenzie ANJ, Menon S, Zurawski G, de Waal Malefyt R, de Vries JD. Interleukin-13 induces interleukin-4-independent IgG4 and IgE synthesis and CD23 expression by human B cells. Proc Natl Acad Sci USA 1998; 90: 3730.
- 35 Larocque R, Robinson MA. Diversity in the human T cell receptor beta chain. Hum Immunol 1996; 48: 3-11.
- 36 Shevach EM, Rosenthal AS. Function of macrophages in antigen recognition by guinea pig T lymphocyptes. II. Role of the macrophage in the regulation of genetic control of the immune response. J Exp Med 1973; 138: 1213-1229.
- 37 Mayr WR, Lechner K, Niessner H, Pabinger-Fasching I. HLA-DR and factor VIII antibodies in hemophilia A. Thromb Haemost 1984; 51: 293.
- 38 Lippert LE, Fisher LM, Schook LB. Relationship of major histocompatibility complex class II genes to inhibitor antibody formation in hemophilia A. Thromb Haemost 1990; 64: 564-568.
- 39 Aly AM, Aledort LM, Lee TD, Hoyer LW. Histocompatibility antigen patterns in haemophilic patients with factor VIII antibodies. Br J Haematol 1990; 76: 238-241.
- 40 Hay CRM, Ollier W, Pepper L, Cumming A, Keeney S, Goodeve AC, Colvin BT, Hill FGH, Preston FE, Peake IR. for the UKHC-DO Inhibitor Working Party. HLA class II profile. A weak determinant of factor VIII inhibitor development in severe haemophilia A. Thromb Haemost 1997; 77: 234.
- 41 Oldenburg J, Picard J, Schwaab R, Brackman HH, Tuddenham EGD, Simpson E. HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII. Thromb Haemost 1997; 77: 238-242.
- 42 Theofilopoulos A. The basis of autoimmunity: part II. Genetic predisposition. Immunol Today 1995; 16: 150-159.
- 43 Hershey GK, Friedrich M, Esswein LA, Thomas ML, Chatila TA. The association of atopy with a gain-of-function mutation in the subunit of the interleukin-4 receptor. N Engl J Med 1997; 337: 1720-1725.